about
Evaluation of the quality of guidelines for myasthenia gravis with the AGREE II instrumentInternational consensus guidance for management of myasthenia gravis: Executive summaryPrecision medicine in myasthenia graves: begin from the data precisionClinical profile of patients with myasthenia gravis followed at the University Hospital, Federal University of Minas Gerais.Determinants of quality of life in Brazilian patients with myasthenia gravis.The MG Composite: A valid and reliable outcome measure for myasthenia gravis.Neurologic indications for therapeutic plasma exchange: an update.Neurologic indications for therapeutic plasma exchange: 2011 update.Psychometric evaluation of the myasthenia gravis composite using Rasch analysis.Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items".Neurologic indications for therapeutic plasma exchange: 2013 update.Randomized Trial of Thymectomy in Myasthenia GravisThymoma and autoimmunity.Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe diseaseEarly fast-acting treatment strategy against generalized myasthenia gravis.CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population.Quality of life in purely ocular myasthenia in Japan.A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.Juvenile myasthenia gravis: a paediatric perspectiveNationwide population-based epidemiological study of myasthenia gravis in taiwanThe association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.Myasthenia Gravis Presenting as Persistent Unilateral Ptosis with Facial Droop.Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis.Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study.An up-date on health-related quality of life in myasthenia gravis -results from population based cohortsA Challenging Diagnosis of Fluctuating Dyspnea: Myasthenia GravisComplicating autoimmune diseases in myasthenia gravis: a review.Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort studyApplying complement therapeutics to rare diseases.Myasthenia gravis: a review.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Myasthenia gravis presenting like guillain-barré syndrome.Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations.Myasthenia gravis: a clinical-immunological update.Myasthenia gravis and stroke in the setting of giant cell arteritis.Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.Clinical Profile and Outcome of Postthymectomy versus Non-Thymectomy Myasthenia Gravis Patients in the Philippine General Hospital: A 6-Year Retrospective Study.Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityFatigue in myasthenia gravis: risk factors and impact on quality of life.
P2860
Q21131900-BB063956-B325-42F7-B7D7-86275A1058A0Q26746047-48A79B1C-977B-44B2-8513-A9A25EC4BCBEQ26748943-CC6449E6-7438-4E87-8350-931E8DB9874BQ30279121-61C803D7-6FC2-4EF1-BA51-0CF7CF9448CFQ30357085-27DCC12D-803F-43A9-A28A-25EE8A0CF776Q30424639-6918E640-6BE0-4F40-86BB-C7C8DDE75155Q30454297-F71973F0-48AA-4E77-BF54-7F55F5DD9240Q30455391-6B1629FA-19F6-4792-9C6C-EABFDC4F5615Q30455482-EF5F0354-7680-4067-B105-061CEFEEF27DQ30457240-5479F804-5FF0-4A72-B7E8-584AB6265A62Q30458271-40863F97-9D7E-4D4C-86D0-2DB3A17DDC06Q30833195-105A6244-2BC0-4511-B904-257421081E12Q33577486-956AB0C6-E67C-4B69-89E0-DFD32A589FC0Q33666033-DB635A40-F26A-4E5B-8641-7B9AB6263FADQ33834012-9A6FA54C-C209-49A7-AEE5-5EDA70ED598EQ33864254-CDF3D172-4ACE-4650-BF7E-9A2394EBF2B2Q33869796-D3047702-3DC1-4A26-8A06-C34010B55AB5Q33983913-000BF414-937D-4052-BF11-83B49C196966Q34029492-298BD9D3-0BF0-4884-981A-A6390946040FQ34057165-C79A8A16-DB7F-490E-8526-CDF95C7FEEC9Q34240032-AE0CF081-A866-4080-AC88-9A6B114E47BEQ34503367-24493C78-318A-4D03-A07B-F31E337BAAFFQ35768030-6E7923F1-2664-4A3E-9FB9-62E088411722Q35794114-1D206AF3-00D8-465F-91F9-A18D256BA161Q35877852-5F60D919-1F6E-4006-93DD-9186F3CBAF69Q35908237-C5EC8AEA-044E-4503-8AAB-26070FAAFA1DQ35918147-3C4FFBAE-25F3-4CBF-8140-F99A85504EA1Q36192435-59757FB2-435A-452D-AEA3-898B5D406345Q36195417-ABAF2F26-7F3E-425C-88FC-50F80F3B15ECQ36315497-CB9951CF-A4DA-45E3-8C7E-C48678E6FDA8Q36410472-F7DDC508-BDB3-42AC-9B77-F985435AB6EDQ36484383-A6C5DE88-4C53-43ED-AF96-845C4B6D6CD7Q36486729-BDC4AFBD-4B34-4551-B4BE-9F9DBB3305FDQ36568293-5A7B5BF2-5E54-4DF6-9BBA-6ED50FCD1CCBQ36783864-FD04F82B-72B2-4D1C-B286-C5A71A7BCB6DQ36921616-56384E9E-330A-4FA9-BEEA-2359398E6C12Q37015471-B81998A4-2121-469E-8D12-2E702FCACFABQ37022836-3D0B52CF-196E-48FA-820B-4C4CF65F59FFQ37315963-2789F8A5-10B4-4C39-B85D-29F27E58669BQ37339784-2644C4F4-9955-496F-BAB1-0C41D344858C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lifetime course of myasthenia gravis.
@en
Lifetime course of myasthenia gravis.
@nl
type
label
Lifetime course of myasthenia gravis.
@en
Lifetime course of myasthenia gravis.
@nl
prefLabel
Lifetime course of myasthenia gravis.
@en
Lifetime course of myasthenia gravis.
@nl
P2093
P356
P1433
P1476
Lifetime course of myasthenia gravis.
@en
P2093
David Grob
Murali Pagala
Norman Brunner
Tatsuji Namba
P304
P356
10.1002/MUS.20950
P577
2008-02-01T00:00:00Z